// App-Quantinova.ai

14387 : Dose-Related Reductions in Blood Pressure With a RNA Interference (RNAi) Therapeutic Targeting Angiotensinogen in Hypertensive Patients: Interim Results From a First-In-Human Phase 1 Study of ALN-AGT01

Researchers

Presenter

  • Stephen A Huang

Principal Investigators

  • Jorg Taubel

  • Giuseppe Fiore

  • Peter Dewland

  • George L Bakris

  • Akshay S Desai

  • Yansong Cheng

  • Sagar Agarwal

  • Jamie Harrop

  • Huy V Nguyen

  • Jiandong Lu

  • Don Foster

  • Akshay Vaishnaw

  • Jae B Kim

Medical Centers

  • ALNYLAM PHARMACEUTICALS, Cambridge, MA

  • RICHMOND RESEARCH INSTITUTE, London

  • MEDICINES EVALUATION UNIT LTD., United Kingdom

  • MAC CLINICAL RESEARCH, United Kingdom

  • UNIVERSITY CHICAGO MEDICINE, Chicago, IL

  • BRIGHAM AND WOMENS HOSPITAL, Boston, MA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Hypertension

Biomarkers

  • Angiotensinogen

  • Sex hormone binding globulin

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Placebo Control

  • Multicenteric

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved